NCT00002191View on ClinicalTrials.gov

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Protozoan InfectionsHIV Infections
Interventions
DRUG

Albendazole

Trial Locations (6)

10016

New York Univ, New York

10025

Saint Luke's Hosp / Services and Research 1301, New York

20037

George Washington Univ 5-403A, Washington D.C.

94110

San Francisco Gen Hosp / Div of GI, San Francisco

94114

Davies Med Ctr, San Francisco

02215

Deaconess Hosp / Harvard Med School / Infect Disease, Boston

Sponsors

Lead Sponsor

SmithKline Beecham
All Listed Sponsors
lead

SmithKline Beecham

INDUSTRY

NCT00002191 - A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis | Biotech Hunter | Biotech Hunter